Two policy strategies have been pursued to moderate spending on infused cancer biologics. The competition strategy seeks to stimulate market entry by biosimilars, under the principle that newer ...

Within ten years, a patient may find that even a decades-old biologic treatment option they need has no other lower-cost alternative — and the one that’s available is prohibitively expensive and not ...

Source: Getty Images Factors preventing use of biosimilars in oncology include the cost and complexity of development, oncologists’ lack of knowledge, and interactions between payers and pharmacy ...

Biosimilars are often promoted as cost-saving alternatives to their reference medications. Designed to provide comparable therapeutic efficacy at a reduced price, they have the potential to lower ...

Biological products, or biologics, are large, complex molecules produced in living systems such as therapeutic proteins, antibodies, and gene- or cell-based therapies. Under the Public Health Service ...

Biosimilars undergo rigorous comparison with their reference product to ensure pharmacokinetic (PK) and pharmacodynamic similarities, immunogenicity, and efficacy, but any data limitations must be ...

The U.S. Food and Drug Administration (FDA)’s March 2026 update to its biosimilar Q&A guidance arrives at a critical inflection point for the biopharmaceutical sector, as the industry faces a looming ...